imatinib mesylate has been researched along with Germinoblastoma in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, M; Bröckelmann, PJ; Wienemann, H | 1 |
| Ban, H; Hostetler, BJ; McKallip, RJ; Uchakina, ON | 1 |
| Cochet, H; Hennig, A; Leger, A; Peyrou, J | 1 |
| Badowska, W; Ćwiklińska, M; Drabko, K; Janeczko-Czarnecka, M; Januszkiewicz-Lewandowska, D; Karolczyk, G; Karpińska-Derda, I; Kałwak, K; Kołtan, A; Krawczuk-Rybak, M; Musioł, K; Mycko, K; Niedźwiecki, M; Ociepa, T; Pawelec, K; Rybka, B; Ryczan-Krawczyk, R; Ussowicz, M; Zaucha-Prażmo, A | 1 |
| Despas, F; Laurent, G; Roche, H | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Esmailzadeh, S; Jiang, X | 1 |
| Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B | 1 |
| Bain, B | 1 |
| Kees, UR | 1 |
| Bhalla, K; Cheng, F; Cuenca, A; Horna, P; Sotomayor, EM; Wang, H; Zheng, Z | 1 |
| Blay, JY; Bompas, E; Velay, B | 1 |
| Heinemann, V; Hiddemann, W | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Kanakura, Y; Matsumura, I | 1 |
| Grossbard, ML | 1 |
| Casadevall, N; Delmer, A; Legrand, O; Marie, JP; Rio, B; Ugo, V | 1 |
6 review(s) available for imatinib mesylate and Germinoblastoma
| Article | Year |
|---|---|
[Anticancer drug adherence].
Topics: Administration, Oral; Age Factors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Medication Adherence; Neoplasms; Physician's Role; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Socioeconomic Factors | 2013 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Mice; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Piperazines; Pyrimidines | 2011 |
[Current progress in therapy of malignant diseases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Neoplasms; Piperazines; Pyrimidines | 2005 |
[Molecular targeting therapy of hematopoietic tumors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Piperazines; Pyrimidines; Rituximab | 2006 |
[Update on malignant hemopathies].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotoxins; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Tretinoin | 2002 |
11 other study(ies) available for imatinib mesylate and Germinoblastoma
| Article | Year |
|---|---|
[Complete remission of Loeffler's endocarditis with Imatinib in a myeloid and lymphoid neoplasm associated with eosinophilia].
Topics: Antineoplastic Agents; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma; Male; Middle Aged | 2020 |
Treatment of Hematological Malignancies with Glycyrrhizic Acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Glycyrrhizic Acid; Hematologic Neoplasms; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Lymphoma; Mice; Neoplasm Transplantation; Reactive Oxygen Species | 2017 |
Endomyocardial fibrosis in a context of peritonitis.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Cardiomyopathy, Restrictive; Drug Therapy, Combination; Emergency Service, Hospital; Endomyocardial Fibrosis; Epstein-Barr Virus Infections; Follow-Up Studies; Furosemide; Humans; Image Enhancement; Imatinib Mesylate; Lymphoma; Magnetic Resonance Imaging, Cine; Male; Peritonitis; Thrombolytic Therapy; Tomography, X-Ray Computed; Young Adult | 2017 |
Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Poland; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured | 2004 |
The idiopathic hypereosinophilic syndrome and eosinophilic leukemias.
Topics: Benzamides; Clone Cells; Cytokines; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma; Models, Biological; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; T-Lymphocyte Subsets | 2004 |
Gene expression signatures in lymphoid tumours.
Topics: Antineoplastic Agents; Benzamides; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; RNA, Messenger | 2004 |
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
Topics: Amino Acid Sequence; Animals; Antigen-Presenting Cells; Antineoplastic Agents; Benzamides; Bone Marrow Cells; CD4-Positive T-Lymphocytes; Dendritic Cells; Imatinib Mesylate; Immune Tolerance; Lymphoma; Macrophages; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neoplasms; Ovalbumin; Peptide Fragments; Piperazines; Pyrimidines | 2005 |
Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Piperazines; Prednisolone; Pyrimidines; Recurrence; Rituximab; Vincristine | 2004 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Hematologic malignancies: selected abstracts and commentary.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunoconjugates; Leukemia; Lymphoma; Piperazines; Pyrimidines | 2000 |